FOLH1 and neoplasm: An identical PSMA-positive tumor model was utilized.Xenograft growth was assessed following treatment with [67Cu]-SarbisPSMA or [177Lu]-PSMA for imaging and therapy.[177Lu]-PSMA is an FDA-approved tracer for treating prostatecancer.